Business Wire

Nike Kicks Off Multi-Year Innovation Cycle

11.4.2024 21:31:00 EEST | Business Wire | Press release

Share

Today, NIKE, Inc. (NYSE: NKE) extended its position as the undisputed leader of footwear and apparel innovation by debuting a new line-up of products that signaled a multi-year innovation cycle. Brought to life by the full power of digital capabilities and cutting-edge technology, the company is delivering better, faster, more efficient solutions for athletes this summer and opening a world of creative possibilities — including Nike's first sculpted, visible Air Zoom unit in the new Pegasus Premium running shoe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411422311/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Harnessing its proprietary Air technology, Nike debuts the Nike Pegasus Premium – taking the cushioning that runners love from the iconic Pegasus franchise and adding Nike’s first sculpted, visible Air Zoom unit. The new, sculpted Air Zoom unit is the brand’s biggest Air innovation since the launch of the Nike Air VaporMax. (Photo: Business Wire)

The proprietary, sculpted Air unit connects the heel and forefoot and uniquely contours to the natural profile of the foot, delivering an entirely new springy, smooth sensation. Combined with ZoomX and ReactX foam, the new cushioning system creates more energy return for everyday runners.

In addition, Air, Nike’s most revolutionary, ubiquitous and versatile cushioning platform, powers the products Nike athletes will wear on the track, court and pitch this summer. Nike has optimized Air by leveraging computational design and incomparable athlete data from the Nike Sport Research Lab to create footwear that helps all athletes break barriers.

“For more than 50 years we’ve listened to and over-delivered for our athletes with the best of Nike innovation. We always push the boundaries of what’s possible and take risks to help create the future of sport together,” said John Hoke, Nike’s Chief Innovation Officer. “This summer, the difference maker is the massive energy return that Nike Air delivers to athletes. Taking what we learned from our super-shoe technology, we’re introducing new Nike Air Zoom shapes and sensations across all sports.”

The best of Nike’s Air innovation for this summer will debut in the Nike Blueprint Pack, spanning footwear for track and road racing, basketball, football, skate, breakdancing and lifestyle. The blue, white and orange colorway is a nod to Nike’s co-founder, Bill Bowerman, and his obsession with enabling the best-possible athlete performance.

Nike’s world-class athletes, including Dina Asher-Smith, Shelly-Ann Fraser-Pryce, Eliud Kipchoge and Sha’Carri Richardson, revealed the brand’s 2024 federation kits, which are the most data-driven and visually unified Nike’s ever produced. Based on 4D motion-capture data, with pixel-level precision and specifically designed for each competition, the kits were inspired by the distinct identities and diverse communities of each country and sport.

Nike also revealed A.I.R.Athlete Imagined Revolution. In this co-creation project between elite athletes and Nike designers, Nike used innovative design tools to create the future of Air. The radical concepts are a view into the future of athlete co-creation, as well as the unlimited possibilities of Nike Air.

“There are now no limits to what we can create with Nike Air,” said Hoke. “We’re obsessing new technologies like AI engines and rapid prototyping to continue exploring the unlimited possibilities. Now we can create Nike products with unprecedented fidelity, velocity and impact.”

“We’re thrilled to celebrate another summer of sport with our incredible athletes and the product innovations that will help propel them to achieve their dreams,” said Heidi O’Neill, President, Consumer, Product and Brand, NIKE, Inc. “What you’ll see this year on the pitch, court, road or track signals a new, exciting multi-year cycle of innovation for us. And this summer is just a hint of the game-changing innovations coming across our entire portfolio that will take us into new markets and market share opportunities.”

About NIKE, Inc.

NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com. Individuals can also visit http://news.nike.com and follow @NIKE.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

media.relations@nike.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release

Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release

As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye